analytical standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
The neptunium antimonide compound NpSb was produced in 1971 by placing equal quantities of both elements in a vacuum tube, heating them to the melting point of antimony, and then heating it further to 1000 °C for sixteen days. This procedure also produced trace amounts of an additional antimonide compound Np3Sb4. One neptunium-bismuth compound, NpBi, has also been reported. The neptunium carbides NpC, Np2C3, and NpC2 (tentative) have been reported, but have not characterized in detail despite the high importance and utility of actinide carbides as advanced nuclear reactor fuel. NpC is a non-stoichiometric compound, and could be better labelled as NpCx (0.82 ≤ x ≤ 0.96). It may be obtained from the reaction of neptunium hydride with graphite at 1400 °C or by heating the constituent elements together in an electric arc furnace using a tungsten electrode. It reacts with excess carbon to form pure Np2C3. NpC2 is formed from heating NpO2 in a graphite crucible at 2660–2800 °C.
The two studies where inconclusive for other outcome measures (including all-cause and cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure, serious and non‐serious adverse events (increased “non‐serious side effects” where concluded only for acarbose), hypoglycaemia, measures of blood glucose control, blood lipids, body weight, and blood pressure).
== Arrival of the Russian army in Abkhazia == On 3 August 2008, Ogoniok reported that journalist had witnessed Russian military convoy entering Abkhazia on the Russo-Abkhaz border in late July 2008. There had been non-stop movement of the railway echelons in Abkhazia several weeks earlier and that between forty-five and fifty railway cars with tanks had entered the Gali district on the Abkhaz-Georgian border. It also reported that the quantity of armaments and ammunition in Abkhazia was enough to wage a conflict for several years. An unnamed Russian colonel from the peacekeeping forces told journalist that he was expecting that "something will happen." Journalist witnessed that "special-looking" men were crossing the Russo-Abkhaz border. Abkhaz leader Sergei Bagapsh said to journalist: "We are ready for the war, but I am not about to tell the whole world in detail how we have prepared ourselves." Abkhaz leader also commented on the Georgian presence in the Kodori Valley, "You know, we can not indefinitely tolerate their antics in our backyard. It is time to put things in order there." Although Bagapsh had hinted at something, he added that the Abkhaz would never shoot first towards Georgia. In January 2015, resident of Sochi, Oksana Sevastidi, was arrested for treason. She had sent a SMS to the Georgian friend in 2008 in which she reported on the movement of the Russian troops by the railroad to the Abkhaz border before the war. In March 2015, the Supreme Court of Russia reviewed a case of a woman from Sochi, who was accused of treason.
==== Heart ==== In 2012, stem cells were studied in people with severe heart disease. The work by Bodo-Eckehard Strauer was discredited by identifying hundreds of factual contradictions. Among several clinical trials reporting that adult stem cell therapy is safe and effective, actual evidence of benefit has been reported from only a few studies. Some preliminary clinical trials achieved only modest improvements in heart function following the use of bone marrow stem cell therapy. Stem-cell therapy for the treatment of myocardial infarction usually makes use of autologous bone marrow stem cells, but other types of adult stem cells may be used, such as adipose-derived stem cells. Possible mechanisms of recovery include:Generation of heart muscle cells, Stimulating growth of new blood vessels to repopulate damaged heart tissue and secretion of growth factors.
Sources: en.wikipedia.org
The Neanderthal skull has a flat and broad skullcap, rounded supraorbital torus (the buldge that forms the brow ridges), larger, wide orbits (eye sockets), a broad nose, mid-facial prognathism (the face projects far from the base of the skull), an "en bombe" (bomb-like) skull shape when viewed from the back, a fossa (depression) on the back of the skull below the level of the inion (suprainiac fossa), and an occipital bun (bony projection) at the back of the skull. Like those of other archaic humans, their jaws lack a true chin. The Neanderthal braincase averages 1,640 cm3 (100 cu in) for males and 1,460 cm3 (89 cu in) for females, which is significantly larger than the averages for all 147 homonids studied. The largest Neanderthal brain, Amud 1, was calculated to be 1,736 cm3 (105.9 cu in), one of the largest ever recorded in humans. Neanderthal brain organisation differs in areas related to cognition and language, which may be implicated in the comparative simplicity of Neanderthal behaviour to Cro-Magnons in the archaeological record. Neanderthals had large and wide noses, probably an adaptation to warm greater quantities of cold air to fuel their assumed heightened metabolism and activity levels. A large nose does not necessarily equate to a better sense of smell, and neurologically, because the olfactory bulbs are smaller, Neanderthals may have had a poorer sense of smell and olfactory memory than modern humans.
On September 21, 2022, days before declaring the annexation of additional parts of Ukraine, Putin claimed in a national television address that high NATO officials had made statements about the possibility of "using nuclear weapons of mass destruction against Russia", and stated "if the territorial integrity of our country is threatened, we will certainly use all the means at our disposal to protect Russia and our people... It's not a bluff." NBC News characterized Putin's statements as a "thinly veiled" threat that Putin was willing to risk nuclear conflict if necessary to win the war with Ukraine. Hans M. Kristensen, director of the Nuclear Information Project at the Federation of American Scientists, stated that "if you start detonating nuclear weapons in the [battlefield] you potentially get radioactive fallout that you can't control — it could rain over your own troops as well, so it might not be an advantage to do that in the field." According to researcher Ryan Snyder the lethality of long-range precision conventional weapons may now possess lethalities against strategic missile silos comparable to those of nuclear-armed ballistic missiles. According to a peer-reviewed study published in the journal Nature Food in August 2022, a full-scale nuclear war between the U.S. and Russia would kill 360 million people directly, with a further 5 billion people dying from starvation. More than 2 billion people would die from a smaller-scale nuclear war between India and Pakistan. In March 2026, U.S.
The benefit of galcanezumab was assessed based on the change from baseline in the number of migraine days per month during the three-month treatment period, comparing the galcanezumab and placebo groups. In a third study of 1,117 participants who had migraines for more than fifteen days a month on average (chronic migraine), those treated with galcanezumab had on average around five fewer days with migraines per month compared with around three fewer days for participants on placebo. The effectiveness of galcanezumab for the treatment of episodic cluster headache was demonstrated in a clinical trial that compared it to placebo in 106 participants. The trial measured the average number of cluster headaches per week for three weeks and compared the average changes from baseline in the galcanezumab and placebo groups. During the three-week period, participants taking galcanezumab experienced 8.7 fewer weekly cluster headache attacks than they did at baseline, compared to 5.2 fewer attacks for participants on placebo.
Sources: en.wikipedia.org
Lambda (written λ, in lowercase) is a non-SI unit of volume equal to 10−9 m3, 1 cubic millimetre (mm3) or 1 microlitre (μL). Introduced by the BIPM in 1880, the lambda has been used in chemistry and in law for measuring volume, but its use is not recommended. This use of λ parallels the pre-SI use of μ on its own for a micrometre and γ for a microgram. Although the use of λ is deprecated, some clinical laboratories continue to use it. The standard abbreviation μL for a microlitre has the disadvantage that it can be misread as mL (a unit 1000 times larger). In pharmaceutical use, no abbreviation for a microlitre is considered safe. The recommended practice is to write "microlitre" in full.
== Legal status == Dioxaphetyl butyrate is listed as an internationally controlled opioid under Schedule I of the 1961 Single Convention on Narcotic Drugs.[ref] In Australia, the Office of Drug Control lists it as a narcotic requiring import and export licensing and permits. In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9621 and a 2013 annual aggregate manufacturing quota of zero.
=== Polysaccharides === Certain compounds found in mushrooms, primarily polysaccharides, can up-regulate the immune system and may have anti-cancer properties. For example, beta-glucans such as lentinan have been shown in laboratory studies to stimulate macrophage, NK cells, T cells and immune system cytokines and have been investigated in clinical trials as immunologic adjuvants.
Despite the generally higher volume fraction of rays in hardwoods (typically 15% of wood volume), the rays are not particularly effective in radial flow, nor are the pits on the radial surfaces of fibres effective in tangential flow.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.